The return on investment of a medicaid tobacco cessation program in Massachusetts

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Richard, Patrick ^a,c   West, Kristina ^a   Ku, Leighton ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COUNSELING; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HEALTH SURVEY; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INVESTMENT; MALE; MEDICAID; SMOKING CESSATION PROGRAM; TOBACCO; UNITED STATES; ADOLESCENT; ALGORITHM; ECONOMICS; EVALUATION; MIDDLE AGED; SMOKING; SMOKING CESSATION; STATISTICS;

NICOTIANA TABACUM;

ADOLESCENT; ADULT; ALGORITHMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INVESTMENTS; MALE; MASSACHUSETTS; MEDICAID; MIDDLE AGED; SMOKING; TOBACCO USE CESSATION; UNITED STATES; YOUNG ADULT;

EID: 84855419746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029665     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention (2010) Vital signs: Current cigarette smoking among adults aged ≥18 years-United States, 2009. MMWR 59 (35): 1135-1140.
2. Centers for Disease Control and Prevention (2009) State-specific smoking-attributable mortality and years of potential life lost-United States, 2000-2004. MMWR 58 (02): 29-33.
3. Centers for Disease Control and Prevention (2009) Adult cigarette smoking in the United States: current estimate. Available: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm. Accessed 2011 Aug 05.
4. Centers for Disease Control and Prevention (2008) Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMWR 57 (45): 1226-28.
5. Armour BS, Finkelstein EA, Fiebelkorn IC, (2009) State-level Medicaid expenditures attributable to smoking. Prev Chronic Dis 6 (3): 1-10.
6. Office of the Surgeon General. Healthy People 2020: Summary of Objectives. Available: http://www.healthypeople.gov/2020/topicsobjectives2020/pdfs/TobaccoUse.pdf. Accessed 2011 Aug 09.
7. McMenamin SB, Halpin HA, Ingram M, Rosenthal A, (2010) State Medicaid coverage for tobacco-dependence treatments - United States, 2009. MMWR 59 (41): 1340-1343.
8. Massachusetts Tobacco Cessation Program. MassHealth Tobacco Cessation Program: Factsheet for Providers. No date. Available: http://quitworks.makesmokinghistory.org/uploads/section_quitworks/masshealth/ProviderFactSheet_ServiceRates.pdf. Accessed 2011 Nov 11.
9. Land T, Warner D, Paskowsky M, Cammaerts A, Wetherell L, et al. (2010) Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in smoking prevalence. PLoS ONE 5: e9770 doi:10.1371/journal.pone.0009770.
10. Land T, Rigotti N, Levy D, Paskowsky M, Warner D, et al. (2010) A longitudinal study of Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in hospitalizations for cardiovascular diseases. PLoS Med 7 (12): e1000375 doi:10.1371/journal.pmed.1000375.
11. Fiore MC, Jaén CR, Baker TB, Bailey W, Benowitz N, et al. (2008) Treating tobacco use and dependence: quick reference guide for clinicians, 2008 update. US Department of Health and Human Services.
12. Hajek P, Stead LF, West R, Jarvis M, Lancaster T, (2009) Relapse prevention interventions for smoking cessation. Cochrane Database System Rev 1 pp. CD003999.
13. Nides M, (2008) Update on pharmacologic options for smoking cessation treatment. Am J Med 121 (4 Suppl 1): S20-31.
14. Stead LF, Perera R, Bullen C, Mant D, Lancaster T, (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 1 pp. CD000146.
15. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, et al. (2006) Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (1): 47-55.
16. Keating GM, Lyseng-Williamson KA, (2010) Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 28 (3): 231-54.
17. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 430 (9): 685-91.
18. Zimovetz E, Wilson K, Samuel M, Beard S, (2011) A review of cost-effectiveness of treatment for major smoking-related morbidities. J Eval Clin Pract 17 (2): 288-97.
19. Ladapo J, Jaffer F, Weinstein M, Froelicher E, (2011) Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. Arch Intern Med 171 (1): 39-45.
20. Agency for Healthcare Research and Quality (2011) HCUP Clinical Classification Software. Appendix A. Single Diagnosis Codes. Revised Oct. 28, 2011. Available: http://www.hcup-us.ahrq.gov/toolssoftware/ccs/AppendixASingleDX.txt. Accessed 2011 Nov 11.
21. Aday LA, Andersen R, (1974) A framework for the study of access to medical care. Health Serv Res 9 (3): 208-220.
22. Duan N, Manning W, Morris C, Newhouse J, (1983) A comparison of alternative models for the demand for medical care. J Bus & Econ Stat 1 (2): 115-26.
23. Buntin M, Zaslavsky A, (2004) Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 23: 525-42.
24. Manning WG, Mullahy J, (2001) Estimating log models: to transform or not to transform? J Health Econ 20 (4): 461-494.
25. Kahn R, Robertson R, Smith R, Eddy D, (2008) The impact of prevention on reducing the burden of cardiovascular disease. Circulation 118: 576-85.
26. Ku L, (2010) Ready, set, plan, implement: Executing Medicaid's expansion. Health Aff (Millwood) 29 (6): 1173-77.